Enanta Pharmaceuticals, Inc.
ENTA
$11.35
$0.282.53%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 17.16M | 18.62M | 15.13M | 18.31M | 14.93M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.16M | 18.62M | 15.13M | 18.31M | 14.93M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 17.16M | 18.62M | 15.13M | 18.31M | 14.93M |
| SG&A Expenses | 9.57M | 9.01M | 9.70M | 10.00M | 11.39M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.01M | 29.87M | 33.51M | 37.21M | 39.45M |
| Operating Income | -11.85M | -11.25M | -18.39M | -18.89M | -24.53M |
| Income Before Tax | -13.08M | -11.91M | -18.67M | -18.23M | -23.95M |
| Income Tax Expenses | 7.00K | 24.00K | 32.00K | 29.00K | -1.31M |
| Earnings from Continuing Operations | -13.09M | -11.94M | -18.70M | -18.26M | -22.64M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.09M | -11.94M | -18.70M | -18.26M | -22.64M |
| EBIT | -11.85M | -11.25M | -18.39M | -18.89M | -24.53M |
| EBITDA | -10.64M | -10.02M | -17.10M | -17.68M | -23.32M |
| EPS Basic | -0.45 | -0.42 | -0.87 | -0.85 | -1.06 |
| Normalized Basic EPS | -0.28 | -0.26 | -0.57 | -0.53 | -0.70 |
| EPS Diluted | -0.45 | -0.42 | -0.87 | -0.85 | -1.06 |
| Normalized Diluted EPS | -0.28 | -0.26 | -0.57 | -0.53 | -0.70 |
| Average Basic Shares Outstanding | 29.04M | 28.75M | 21.38M | 21.38M | 21.36M |
| Average Diluted Shares Outstanding | 29.04M | 28.75M | 21.38M | 21.38M | 21.36M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |